chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Date the vial was initially stored in the refrigerator on 30Jun2022, Date of administration of vaccine on 02Aug2022; No adverse reaction; Used Moderna Covid-19 vaccine last week beyond its use by date.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Used Moderna Covid-19 vaccine last week beyond its use by date.), PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator on 30Jun2022, Date of administration of vaccine on 02Aug2022) and NO ADVERSE EVENT (No adverse reaction) in a 59-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 01-Aug-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 01-Aug-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Used Moderna Covid-19 vaccine last week beyond its use by date.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator on 30Jun2022, Date of administration of vaccine on 02Aug2022) and NO ADVERSE EVENT (No adverse reaction). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Used Moderna Covid-19 vaccine last week beyond its use by date.), PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator on 30Jun2022, Date of administration of vaccine on 02Aug2022) and NO ADVERSE EVENT (No adverse reaction) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse reaction) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Used Moderna Covid-19 vaccine last week beyond its use by date.) and PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator on 30Jun2022, Date of administration of vaccine on 02Aug2022).    Patient had 2nd booster dose. No concomitant medications were provided. The vial was initially stored in refrigerator on 30-Jun-2022. The vial did not undergo any temperature excursions. No treatment medications were reported.
Started having neck pain on a Thursday, my taste buds became less sensitive but I could still taste on Friday and late Saturday night my left side of face started feeling numb. Went to hospital on Sunday morning when I woke up since left side of face was completely numb. Diagnosed with Bell's Palsy.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 78-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 05Mar2022 as dose 4 (booster), single (Lot number: FM069D) at the age of 78 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "known allergy: Sulf" (unspecified if ongoing), notes: known allergy: Sulf. Concomitant medication(s) included: ATORVASTATIN, start date: May2016, stop date: 13Sep2022. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Patient received vaccine. Yes, Other medication received in 2 weeks. Patient was treated with COVID-19 treatment from 13Sep2022 to 17Sep2022. Patient report about COVID treatment.
10 minutes after the vaccine was administered, the patient started presenting a tingling sensation on her throat.  She was given diphenhydramine 50 mg IM.
Information has been received from a physician concerning a 33 year old "healthy" white female patient with no known drug allergies who on 01/06/2004 was vaccinated with a dose of measles virus vaccine live (lot 3 640743/0562N).  There was no illness at the time of vaccination.  It was reported that the patient had a total of five measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live "had all childhood one prior to college".  Subsequently, on 07/06/2004, the patient was "still non-immune" to measles.  It was noted that in January 2004 the patient had transient immunity, "now gone".  Unspecified medical attention was sought.  It was noted that the vaccine was well tolerated. Additional information has been requested. The physician also reported that another patient that was vaccinated with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live was non-immune to the measles.
High temperatures for 2 weeks (pt reported 103) associated with muscular and bone discomfort, nausea, no vomiting, mild shortness of breath without wheezing.  Developed localized swelling at injection site approximately 10X10 cm in size, ass with increase warmth and pain, otherwise physical examination was normal on 5/15/2008 and blood test did not reveal any increased WBC or other abnormalities (Sma20). Two weeks later developed cellulites diagnosed by another physician on 5/25/08 and patient was started on Kelfex.  Since then temperature seems to be resolving, but still some residual muscular pain and also " feeling of fuzziness in brain".
Rash that started morning (1/23) after vaccine was administered. Diffuse erythematous maculopapular rash.  Rash is blanchable. Patient reports it is itchy. Did not apply anything to it or take any medications.  Seen in office on 1/25- advised to try benadryl or zyrtec/claritin as needed for itching.
9 days after vaccine round rash at injection site; arm was red; arm felt hard to move; hard to touch; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MOVEMENT IMPAIRMENT (arm felt hard to move), VACCINATION SITE INDURATION (hard to touch), VACCINATION SITE RASH (9 days after vaccine round rash at injection site) and VACCINATION SITE ERYTHEMA (arm was red) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced VACCINATION SITE MOVEMENT IMPAIRMENT (arm felt hard to move), VACCINATION SITE INDURATION (hard to touch) and VACCINATION SITE ERYTHEMA (arm was red). On 24-Jan-2021, the patient experienced VACCINATION SITE RASH (9 days after vaccine round rash at injection site). On 16-Jan-2021, VACCINATION SITE MOVEMENT IMPAIRMENT (arm felt hard to move), VACCINATION SITE INDURATION (hard to touch) and VACCINATION SITE ERYTHEMA (arm was red) had resolved. On 25-Jan-2021, VACCINATION SITE RASH (9 days after vaccine round rash at injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided by the reporter. No concomitant medications were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Follow up received and reporter contact details were updated.
Mild redness in Left thigh with hematuria of 2cm in diameter. No painful, mild indurated.
pain, redness + swelling at injection site; muscle pain in Lt. upper arm (site of injection), area hot to touch, itching at site, fever, shivering, tiredness, malaise, nausea, no vomiting, slight stomach ache, generalized body aches & pains. No treatment. Drank lots of water and herbal tea & soft diet. Did not work for 2 days. Resolved on its own in 3 days. No medical professional seen. (There is no additional information on continuation page.)
Swollen lymph nodes; Rash at injection site; This is a spontaneous report received from a contactable consumer. The reporter is the patient.  A 41-year-old female patient (not pregnant) received BNT162B2 (BNT162B2), administered in arm right, administration date Mar2021 (Batch/Lot number: unknown) at the age of 41 years as dose 2, single, for COVID-19 immunization. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: BNT162B2 (DOSE 1; 03:30 PM; right arm), administration date: Feb2021, when the patient was 41 years old, for COVID-19 immunization. The following information was reported: LYMPHADENOPATHY (non-serious) with onset Mar2021, outcome "recovered" (Mar2021), described as "Swollen lymph nodes"; VACCINATION SITE RASH (non-serious) with onset Mar2021, outcome "recovered" (Mar2021), described as "Rash at injection site". Therapeutic measures were not taken as a result of lymphadenopathy, vaccination site rash.  Additional Information: The patient was administered with the vaccine in Mar2021 at 16:30. The events were experienced in Mar2021 at 19:00. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not tested for COVID-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
received his second COVID 19 Pfizer shot on March 1 and began feeling bad with cough, aches, no energy and his urine turned brown the day he received the second shot. The next week after getting worst he went to the hospital.  They first diagnosis him with  pneumonia ad kidney failure. They admitted him to the hospital and began running test.  He was then diagnosed with anti-GBM or Goodpasture's Disease.  He had gone to the doctor on the Friday before his second shot on Monday, March 1st and he was very healthy and very active with no health issues.  The second COVID Pfizer shot is the only thing he had done different that week.
Here, brought in by EMS with complaints of having body aches, headaches, some cough, and generally not well since she got her second Covid Vaccine.  She states that she has not been taking any tylenol because she did not have any.  Denies nausea and vomiting and denies any dysuria.  Her friend that is a retired nurse came over to check on her and gave her 1g of Tylenol 70 minutes ago.  EMS stated her temperature was 106.7 on scene, but she is 98.4 here.  She has no other focal complaints, just has felt bad since the second Covid Vaccine.   Her oxygen saturation on admit to the ER was 84%.
Severe swelling of the arm from shoulder to elbow, redness from shoulder to elbow, extreme pain from shoulder to elbow
Hives on trunk of body (back and abdomen) and on thighs - large in size, also c/o itching, took OTC BENADRYL 10/11/14 and 10/12/14. Saw PCP 10/13/14 received "shot" and advised to cont. BENADRYL. 10/14/14 AM hives and itching gone. No problems since.
Information has been received from a physician concerning a 25 year old female who on 17-FEB-2009 was vaccinated with the first dose of GARDASIL (lot number, route an site of administration not reported).  It was reported that "the patient was in the office to receive the first dose of GARDASIL and right after receiving the first dose the patient fainted".  The physician reported that they had helped the patient up then she recovered, so she was ok to leave the office.  The physician also mentioned that the patient did not have anything to eat before getting the first dose of GARDASIL.  Additional information has been requested.
Attendee received second dose Pfizer vaccine at 16:05 in the Left arm.  Lot# FE3594. Attendee was directed to observation area.   At 16:20 voiced complaints of dizziness and fatigue.  Attendee's skin was warm and dry.  Attendee's respirations were not tachypneic or dyspneic. Attendee assisted to the cot to lie down, legs elevated. Water given. HR:  75   BP:  100/80   RR:   18   O2Sat%: 99    Temp:  98.5      16:35 - Attendee stated she felt better.  Attendee refused to have anyone called to the site to pick her up. HR:  80   BP:  100/79   RR:   18   O2Sat%:  99  16:55 -No voiced complaints- skin warm and dry.   HR:  76   BP:  104/80   RR:   18   O2Sat%:  99  Additional information for Item 18:  16:55 - Care Practitioner educated on home discharge/adverse reaction instructions and attendee was discharged to home.   Attendee did not have any reported escalation of symptoms and was able to walk out of clinic independently.  Attendee was retained for a longer observation time to make sure that it was safe for them to leave.
hallucenagetic type dreams repeating in constant loop; fever 101.5F; chills; uncontrollable shaking; sore / achy body and joints; achy body and joints; headache; no appetite; numb tongue; taste like metal; This is a spontaneous report from a non-contactable consumer, the patient. A 68-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot ER8732, first dose) solution for injection intramuscular on 21Apr2021 (at the age of 68-years-old) as a single dose for COVID-19 vaccination. There was no medical history. There were no concomitant medications. The patient had no known allergies. The patient did not receive any other vaccine within 4 weeks prior to the vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 21Apr2021, the patient experienced fever 101.5F and chills, uncontrollable shaking, sore, achy body, and joints, headache, no appetite, numb tongue, taste like metal, hallucenagetic type dreams repeating in constant loop effects began approximately 10 hours after injection. There was no treatment for the events. The outcome of the events fever, chills, uncontrollable shaking, sore, achy body, and joints, headache, no appetite, numb tongue, taste like metal, and hallucenagetic type dreams was recovering. The patient was not tested post vaccination for COVID.  No follow-up attempts are possible. No further information is expected.
Got your vaccine (against my better judgement) and still got the COVID.; Got your vaccine (against my better judgement) and still got the COVID.; This is a spontaneous report received from a contactable consumer (Patient). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number: Not provided) via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient mentioned that your COVID vaccine was a waste of time. I have a good immune system, got your vaccine (against my better judgement) and still got the COVID. This now fits with my theory that the Democrats and Chinese created the virus to get rid of and big pharma went along knowing what a gold mine a new virus and vaccine would mean for the bottom line. Great job. The patient underwent lab tests and procedures which included sars-cov-2 test got covid on an unspecified date.  The lot number for the vaccine, (BNT162B2), was not provided and will be requested during follow up.
This spontaneous report was received from a nurse practitioner regarding an approximately 75 year old patient of unknown gender. On 28-APR-2014 the patient was vaccinated with PNEUMOVAX 23 lot # H020684; expiry: 17-APR-2014, 0.5 ml, intramuscular. No concomitant medications were reported. On 28-APR-2014, nurse reported that patient received an expired dose of PNEUMOVAX 23. No adverse effect was reported. There was no product quality complaint (PQC) involved. The outcome of expired vaccine administered and no adverse effect was reported is unknown. Additional information has been requested.
I have swallow of about 2" and red; I have swallow of about 2" and red; This case was reported by a consumer via call center representative and described the occurrence of erythema in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st May 2020, the patient received Shingrix. In May 2020, less than a week after receiving Shingrix, the patient experienced erythema and swelling. On an unknown date, the outcome of the erythema and swelling were unknown.   It was unknown if the reporter considered the erythema and swelling to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as an adult as per the vaccine indication. The patient received Shingrix and experienced swelling of about 2 inches and redness. The reporter wanted ton know should he/she be concerned.
patient reported, fever of 101.5, chills, headache,  body aches, and fatigue <24 hours after vaccination.  on 2nd day following vaccination, on 8/15/2021, patient reported swollen lymph nodes in left under arm, several swollen lymph nodes, tender the the touch. fever resolved within 24 hours, headache, fatigue, and body aches persisted through the weekend. Lymph nodes still swollen/tender 8/16/2021. all other s/sxs improving at this time.
Injection site tenderness,  ipsilateral rotator cuff tendinopathy,  ipsilateral hand tingling, ipsilateral medial biceps tenderness
Lightedheaded, dizzy,  Bl Glucose 103, P53, B/P 100/45, R 22 15 min observation, released. H
covid-19; covid-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 49-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 04Apr2021 as dose 1, single (Lot number: ER8727), in left arm, on 05May2021 as dose 2, single (Lot number: Er8727), in left arm and on 02Dec2021 at 10:00 as dose 3 (booster), 0.3ml single (Lot number: En0191) at the age of 48 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "high cholesterol" (unspecified if ongoing); "obesity" (unspecified if ongoing); "seasonal allergies" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "covid-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (02Sep2022) Negative; (03Sep2022) Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Patient has no known allergies.
tenderness and swelling of the lymph nodes in the same arm of the injection,  fatigue, headache, muscle pain, , chills, nausea  and fever
I had the 1st GARDASIL vaccination in Oct 2008 and ever since then I have been having high fevers, between to 102-103.0.
Soon after getting the vaccine I noticed swelling on my left arm and a few days later on 2/7/2021 I noticed some lumps on my lower part of my  neck. I contacted my doctor a day or two after to schedule an appointment. My appointment was on February 15, 2021. PA examined  the lumps and she stated that they felt like reactive lymph nodes and she ordered and ultrasound for March 5, 2021.  At the ultrasound appointment they found that the lumps were large and retractive and wanted to follow-up in three months; so they scheduled me another ultrasound appointment, on June 10, 2021.  On  June 10th at my follow-up ultrasound appointment, they stated that the swelling in the  lymph nods went down and returned back to normal.
Approximately 15 minutes after 1st moderna vaccine experienced hot, eyes watering, patient started to feel weak. APRN in room. 1340 NS started, Benedryl 12.5mg IVP given, 1355 Benedryl 12.5mg IVP 2nd dose. 1354 epinephrine auto inject done, 1400 Solumedrol 125mg duoneb tx, EMS transported
Headache, nausea, poor appetite, no fever from 11-4-2010 - 11-8-10. Was able to go to football game & cheer on 11-5-10.
Fever up to 38 celsius. Painful hand. After 24 hours the fever was treated with Excedrin PM.
t102 or 103R responds to APAP but fluctuates especially spikes when asleep, very irritable;devel pneumonia
Inappropriate schedule of vaccine; Soreness at the injection site; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 75-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis and Flu unspecified (Flu vaccine) for prophylaxis.   On 09-MAR-2023, the patient received the 2nd dose of Shingrix (intramuscular, left arm). On 24-AUG-2020, the patient received the 1st dose of Shingrix (intramuscular, unknown arm) and Flu vaccine (unknown arm). On 24-AUG-2020, not applicable after receiving Shingrix and less than a day after receiving Shingrix and Flu vaccine, the patient experienced injection site pain (Verbatim: Soreness at the injection site). On 09-MAR-2023, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate schedule of vaccine). The outcome of the injection site pain was resolved and the outcome of the drug dose administration interval too long was unknown.   It was unknown if the reporter considered the injection site pain to be related to Shingrix and Flu vaccine.     It was unknown if the company considered the injection site pain to be related to Shingrix and Flu vaccine.   Additional Information: GSK Receipt Date: 16-MAY-2023 The reporter stated the patient who received dose of Shingrix with some Flu vaccine (manufacturer not provided) in her right arm and experienced soreness at the injection site, no other information provided.  The patient received second dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule. The reporter did not consent to follow-up.
Information has been received from a consumer concerning his 11 year old son who on approximately 12/24/93, at 12 months old was vaccinated with MMR (lot number not reported). In approximately August 1994, when he was 18 months old he was found to be slightly autistic. The physician was contacted. At the time of this report the patient had not recovered. Upon internal review autism was considered an other important medical event (OMIC). Per follow up report dated 06/09/2005 vaccine recipient has not recovered.